Pipeline
PARTNERS
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
REGISTRATION
Obesity
-
Petrelintide
amylin analog
-
PARTNERS
- Phase 3
-
Petrelintide / CT-388
amylin + GLP-1/GIP
-
PARTNERS
- Phase 1
-
Survodutide
glucagon/GLP-1 receptor dual agonist
-
PARTNERS
- Phase 3
-
ZP6590
GIP receptor agonist
- Preclinical
-
Dapiglutide (program paused)
GLP-1/GLP-2 receptor dual agonist (Phase 2 ready - development paused)
- Phase 1
Congenital Hyperinsulinism
-
Dasiglucagon: Continuous infusion
glucagon analog
- Registration
Short Bowel Syndrome
-
Glepaglutide
GLP-2 analog
- Phase 3
Chronic inflammation
-
ZP9830
Kv1.3 ion channel blocker
- Phase 1
Latest scientific publications
All Scientific publications-
Safety, tolerability, and clinical effects of dapiglutide, a once-weekly GLP-1R/GLP-2R agonist
-
Effects of the novel long-acting amylin analog petrelintide on body weight and waist circumference by sex in a Phase 1 trial
-
Safety, Tolerability, and Clinical Effects of Petrelintide (ZP8396), A Long-acting Amylin Analog
-
Dapiglutide is a dual agonist on human GLP-1- and GLP-2-receptors with a biased and prolonged signaling profile at the GLP-1R
We are leveraging decades of metabolic health experience, spanning incretin biology and peptide engineering, to generate insights that feed our discover engine. We are focused on approaches that rebalance the system and help restore metabolic health.
Utpal Singh
Chief Scientific Officer, Zealand Pharma
